MARIPOSA: First-Line Amivantamab Plus Lazertinib in EGFR-Mutated NSCLC
Focusing on the MARIPOSA trial, the panel provides thoughts the potential role of amivantamab and lazertinib, and discusses treatment decisions upon progression.
FLAURA2: Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC
Medical oncologists review the FLAURA2 study looking at osimertinib with or without chemotherapy in EGFR-mutated NSCLC and discuss patients for whom they would consider the therapy.
NSCLC: Molecular Testing in the Metastatic Setting
The discussion on biomarker testing practices for patients with non–small cell lung cancer turns its focus to the metastatic setting.
Biomarker Testing in Non–Small Cell Lung Cancer
A panel of medical oncologists introduce themselves and provide clinical insights on biomarker testing practices for patients with non–small cell lung cancer.
Key Takeaways for the Treatment of NRG1 Fusion–Positive Malignancies
Alexander I. Spira, MD, PhD, and Joshua K. Sabari, MD, conclude their discussion with key takeaways on the evolving treatment of patients with NRG1 fusion–positive malignancies.
NRG1 Fusions in Pancreatic Cancer and Potential Role of Zenocutuzumab
The expert panel discusses NRG1 fusions in pancreatic cancer and the potential role of zenocutuzumab as a therapeutic option.
Ongoing Research of NRG1-Targeted Therapies
Alexander I. Spira, MD, PhD, and Joshua K. Sabari, MD, discuss ongoing clinical trials focused on NRG1-targeted therapies.
Clinical Diagnosis of NRG1 Fusions in NSCLC
Clinical insights on the diagnosis of NRG1 fusions in patients with non–small cell lung cancer.
Testing for NRG1 Fusions
Medical oncologists review testing practices for NRG1 fusions for patients with pulmonary or gastrointestinal malignancies.
NRG1 Fusions in Lung and GI Cancers
Alexander I. Spira, MD, PhD, and Joshua K. Sabari, MD, discuss the prevalence of NRG1 fusions in pulmonary and gastrointestinal solid tumors and provide an overview of treatment practices.
TROPION-Lung05: Dato-DXd in Previously Treated NSCLC
An expert on lung cancer discusses data from TROPION-Lung05 on datopotamab deruxtecan in patients with previously treated NSCLC with actionable genomic alterations.
MARIPOSA: Amivantamab Plus Lazertinib in EGFR-Mutated Advanced NSCLC
Joshua K. Sabari, MD, reviews the primary results from the MARIPOSA study presented at ESMO 2023 looking at amivantamab plus lazertinib in EGFR-mutated advanced NSCLC.
Frontline Forum: Testing and Targeted Therapy in EGFR Exon20+ NSCLC
Experts discuss the current continuum of care for patients with EGFR exon 20 non–small cell lung cancer and findings from studies including the phase 2 CHRYSALIS trial.
Evolving Management of EGFR Exon20+ NSCLC: Future Directions in Care
Closing out their discussion on EGFR Exon20+ non–small cell lung cancer, Joshua Sabari, MD, and Misako Nagasaka, MD, share excitement for future evolutions in the treatment paradigm.
Advanced NSCLC: CNS Penetration With Novel EGFR TKI Therapy
A brief review of novel EGFR TKIs that may have stronger CNS penetration in patients with non–small cell lung cancer and brain metastases.
Factors in Selecting Novel Therapy for Patients With EGFR Exon20+ NSCLC
Following their review of data behind amivantamab and mobocertinib in EGFR Exon20+ non–small cell lung cancer, expert oncologists consider factors that help to inform treatment selection.
EGFR Exon20+ NSCLC: Trial Data With Mobocertinib
Joshua Sabari, MD, and Misako Nagasaka, MD, reflect on clinical trial data and experience with mobocertinib in patients with EGFR Exon20+ non–small cell lung cancer.
Trial Data and Experience With Amivantamab in EGFR Exon20+ NSCLC
Expert perspectives on clinical trial data and personal experience with amivantamab in the setting of EGFR Exon20+ non–small cell lung cancer.
First- and Second-Line Treatment Options for EGFR Exon20+ NSCLC
Key opinion leaders in non–small cell lung cancer management reflect on the current first- and second-line treatment options available to patients with EGFR Exon20+ disease.
Uncommon EGFR Mutations in Advanced Non–Small Cell Lung Cancer
Shared insight on uncommon EGFR mutations in patients with non–small cell lung cancer and how they fit into the larger disease paradigm.
Paradigm of NGS Testing in Patients With Advanced NSCLC
NSCLC: Moving Second-Line Therapies to Frontline Setting
Helena A. Yu, MD, and Joshua K. Sabari, MD, look to the future of frontline treatment in EGFR exon 20–mutated non–small cell lung cancer.
Clinical Implications of Real-World Amivantamab Data in NSCLC
Lung cancer experts discuss how these real-world data comparing amivantamab with alternative therapies may impact their clinical practice.
Overview of Real-World Comparative Data for Amivantamab in NSCLC
Joshua K. Sabari, MD, and Helena A. Yu, MD, discuss real-world data comparing amivantamab with other therapies in EGFR exon 20–mutated non–small cell lung cancer.
Real-World Analysis of Amivantamab vs Other Therapies in Exon 20–Mutated NSCLC: Methods
A comprehensive overview of the methods utilized in a real-world analysis of amivantamab vs other therapies in patients with EGFR exon 20–mutated NSCLC.
CHRYSALIS: Amivantamab in Patients with Advanced NSCLC
Expert oncologists review the CHRYSALIS trial, which resulted in the approval of amivantamab in the second line for patients with locally advanced or metastatic NSCLC with exon 20 mutations.
Treatment Options for Patients with EGFR Exon 20–Mutated NSCLC
Experts on non–small cell lung cancer discuss treatment options for patients with EGFR exon 20 mutations in the first line and beyond.
Overview of EGFR Exon 20 Mutations
Joshua K. Sabari, MD, and Helena A. Yu, MD, experts on non–small cell lung cancer, give an overview of EGFR exon 20 insertion mutations.